Four world-renowned oncologists selected 20 key, non-small cell lung cancer (NSCLC) abstracts presented at the American Society of Clinical Oncology (ASCO) annual conference. Their goal is to use their platform as educators to share unbiased perspectives on the studies’ clinical data, the methodologies, and its potential for improving patient outcomes in lung cancer.
The success of ASCO 2023 demonstrates the organization’s standing as the preeminent group representing all oncologists. The theme, “Partnering with Patients,” also brought the patient-centric focus to the forefront with the message that without them, innovations, breakthrough therapies, and first-in-class drugs would never have occurred.
The 2023 American Society of Clinical Oncology (ASCO) meeting had implications for patients, physicians and biopharma companies.
The American Society of Clinical Oncology 2023 annual meeting kicked off Friday in Chicago, and BioSpace’s Greg Slabodkin spoke with leading biopharma analysts about the most-anticipated ASCO abstracts.
The latest data, presented at the American Society of Clinical Oncology (ASCO) meeting, establishes Tagrisso as the backbone treatment for EGFR-mutated lung cancer.